Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

The Word Brain 2015Free PDF | Print | Web
A short guide to fast language learning

Free Abstracts

  Malignant Melanoma

  Free Subscription


25.01.2016

2 Am J Ophthalmol
2 Arch Pathol Lab Med
1 Br J Cancer
3 Br J Dermatol
1 Cancer Lett
2 Clin Cancer Res
3 J Am Acad Dermatol
1 J Biol Chem
2 J Clin Invest
1 J Immunother
2 J Surg Oncol
3 Lancet Oncol
4 Melanoma Res
1 Nat Rev Cancer
2 PLoS One
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Ophthalmol

  1. LEE JH, Lee SC, Cho A, Keum KC, et al
    Association Between Choroidal Thickness and Metabolic Activity on Positron Emission Tomography in Eyes With Choroidal Melanoma.
    Am J Ophthalmol. 2016 Jan 14. pii: S0002-9394(16)30003.
    PubMed     Text format    

  2. KAYA A
    Association Between Choroidal Thickness and Metabolic Activity on Positron Emission Tomography in Eyes With Choroidal Melanoma.
    Am J Ophthalmol. 2016 Jan 14. pii: S0002-9394(16)30005.
    PubMed     Text format    


    Arch Pathol Lab Med

  3. HARMS KL, Lowe L, Fullen DR, Harms PW, et al
    Atypical Spitz Tumors: A Diagnostic Challenge.
    Arch Pathol Lab Med. 2015;139:1263-70.
    PubMed     Text format     Abstract available

  4. PANG JC, Roh MH
    Metastases to the Pancreas Encountered on Endoscopic Ultrasound-Guided, Fine-Needle Aspiration.
    Arch Pathol Lab Med. 2015;139:1248-52.
    PubMed     Text format     Abstract available


    Br J Cancer

  5. DIEM S, Kasenda B, Spain L, Martin-Liberal J, et al
    Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma.
    Br J Cancer. 2016 Jan 21. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    Br J Dermatol

  6. MATTER-WALSTRA K, Braun R, Kolb C, Ademi Z, et al
    Treatment specific utility-weightings are needed for cost-utility analysis in metastatic melanoma: reply from the authors.
    Br J Dermatol. 2016 Jan 20. doi: 10.1111/bjd.14279.
    PubMed     Text format    

  7. MULLER C, Wendt J, Rauscher S, Burgstaller-Muehlbacher S, et al
    Characterization of high risk melanoma patients in Austria.
    Br J Dermatol. 2016 Jan 22. doi: 10.1111/bjd.14407.
    PubMed     Text format     Abstract available

  8. CHMIELOWSKI B
    Prognostic and predictive biomarkers for the benefit of immunotherapy in patients with metastatic melanoma.
    Br J Dermatol. 2016;174:20.
    PubMed     Text format    


    Cancer Lett

  9. TANG R, Xu X, Yang W, Yu W, et al
    MED27 promotes melanoma growth by targeting AKT/MAPK and NF-kappaB/iNOS signaling pathways.
    Cancer Lett. 2016 Jan 18. pii: S0304-3835(16)00017.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  10. EKMEKCIOGLU S, Davies MA, Tanese K, Roszik J, et al
    Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and its Expression Associates with Favorable Survival for Stage III Melanoma.
    Clin Cancer Res. 2016 Jan 18. pii: clincanres.2226.2015.
    PubMed     Text format     Abstract available

  11. MARTENS A, Wistuba-Hamprecht K, Geukes Foppen MH, Yuan J, et al
    Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab.
    Clin Cancer Res. 2016 Jan 19. pii: clincanres.2412.2015.
    PubMed     Text format     Abstract available


    J Am Acad Dermatol

  12. BRUNO W, Pastorino L, Ghiorzo P, Andreotti V, et al
    Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup.
    J Am Acad Dermatol. 2016;74:325-32.
    PubMed     Text format     Abstract available

  13. FERRIS LK, Harkes JA, Gilbert B, Winger DG, et al
    Computer-aided classification of melanocytic lesions using dermoscopic images.
    J Am Acad Dermatol. 2015;73:769-76.
    PubMed     Text format     Abstract available

  14. HWANG SJ, Carlos G, Wakade D, Byth K, et al
    Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.
    J Am Acad Dermatol. 2016 Jan 12. pii: S0190-9622(15)02387.
    PubMed     Text format     Abstract available


    J Biol Chem

  15. TITTARELLI A, Janji B, Van Moer K, Noman MZ, et al
    The Selective Degradation of Synaptic Connexin 43 Protein by Hypoxia-induced Autophagy Impairs Natural Killer Cell-mediated Tumor Cell Killing.
    J Biol Chem. 2015;290:23670-9.
    PubMed     Text format     Abstract available


    J Clin Invest

  16. HURST JH
    Cancer immunotherapy innovator James Allison receives the 2015 Lasker~DeBakey Clinical Medical Research Award.
    J Clin Invest. 2015;125:3732-6.
    PubMed     Text format    

  17. COHEN CJ, Gartner JJ, Horovitz-Fried M, Shamalov K, et al
    Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes.
    J Clin Invest. 2015;125:3981-91.
    PubMed     Text format     Abstract available


    J Immunother

  18. LUDLOW SP, Kay N
    Delayed dermatologic hypersensitivity reaction secondary to ipilimumab.
    J Immunother. 2015;38:165-6.
    PubMed     Text format     Abstract available


    J Surg Oncol

  19. HOWIE LJ, Tyler DS, Salama AK
    Neoadjuvant use of ipilimumab in locally advanced melanoma.
    J Surg Oncol. 2015;112:841-3.
    PubMed     Text format     Abstract available

  20. FARLEY C, Alimi Y, Espinosa LR, Perez S, et al
    Tanning beds: A call to action for further educational and legislative efforts.
    J Surg Oncol. 2015;112:183-7.
    PubMed     Text format     Abstract available


    Lancet Oncol

  21. MONCRIEFF M
    Excision margins for melanomas: how wide is enough?
    Lancet Oncol. 2016 Jan 11. pii: S1470-2045(15)00556.
    PubMed     Text format    

  22. BURKI TK
    Defining the genetics of melanoma progression.
    Lancet Oncol. 2015 Nov 19. pii: S1470-2045(15)00537.
    PubMed     Text format    

  23. HAYES AJ, Maynard L, Coombes G, Newton-Bishop J, et al
    Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial.
    Lancet Oncol. 2016 Jan 11. pii: S1470-2045(15)00482.
    PubMed     Text format     Abstract available


    Melanoma Res

  24. MUSTAPHA N, Mokdad-Bzeouich I, Maatouk M, Ghedira K, et al
    Antitumoral, antioxidant, and antimelanogenesis potencies of Hawthorn, a potential natural agent in the treatment of melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available

  25. GLAZER ES, Bartels PH, Lian F, Kha ST, et al
    Quantitative histopathology identifies patients with thin melanomas who are at risk for metastases.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available

  26. SHOUSHTARI AN, Ong LT, Schoder H, Singh-Kandah S, et al
    A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available

  27. KONG BY, Micklethwaite KP, Swaminathan S, Kefford RF, et al
    Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


    Nat Rev Cancer

  28. ALDERTON GK
    Therapeutic resistance: Multiple mechanisms to keep going.
    Nat Rev Cancer. 2015;15:635.
    PubMed     Text format    


    PLoS One

  29. MEHTA K, Appleman L, Wang H, Tarhini AA, et al
    Annual Hospital Volume of High Dose Interleukin-2 and Inpatient Mortality in Melanoma and Renal Cell Carcinoma Patients.
    PLoS One. 2016;11:e0147153.
    PubMed     Text format     Abstract available

  30. SHEEN YS, Liao YH, Lin MH, Chiu HC, et al
    Insulin-Like Growth Factor II mRNA-Binding Protein 3 Expression Correlates with Poor Prognosis in Acral Lentiginous Melanoma.
    PLoS One. 2016;11:e0147431.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  31. FANG M, Hutchinson L, Deng A, Green MR, et al
    Common BRAF(V600E)-directed pathway mediates widespread epigenetic silencing in colorectal cancer and melanoma.
    Proc Natl Acad Sci U S A. 2016 Jan 19. pii: 201525619.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Pfizer Oncology.

Design: